Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2023 Net Income-$14.97M-$14.97MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$15,820,000N/M Operating Cash Flowderived-$13,132,000N/M Free Cash Flowderived-$13,157,000N/M ended Dec 31, 2024 · filed Mar 13, 2025 · 72 d after period end